Browse Tag

cancer research

The AMG 510 model binding the KRAS which is mutant. Binding is irreversible, hindrance constant is viable (nanomolar) in pharmacodynamics terms. Be that as it may, it's effectiveness should be demonstrated clinically. One day this synthetic compound may hit the market and become popular among cancer patients.

March 8, 2021

The drug Fenbendazole can make tumors sensitive to radiotherapy just like agents of chemotherapy

Likewise, it was demonstrated by actualizing high throughput screening in-vitro framework that the drug fenbendazole is successful, not just against standard non-small cell lung cancer, NSCLC, yet in addition against the KRAS-mutant malignancy which seems, by all accounts, aggressive, barely accessible by chemotherapy and

Scientists from the Experimental Drug Development Centre, A*STAR, performing real-time Reverse Transcription-Polymerase Chain Reaction (RT-PCR) to amplify the genetic material from ETC-159 clinical samples. From L-R: Ms Sylvia Gan, Senior Research Manager; Ms Nurul Rozaini, Research Associate (Photo credit: A*STAR)

July 30, 2020

Made-in-Singapore Cancer Drug ETC-159 Advances Further in Clinical Trials

First dose of ETC-159 administered in Phase 1B of clinical trials, advancing

July 9, 2018

How Medical Research Can Tackle the Deadly Legacy of Asbestos

Post world war two, the UK had the difficult task ahead of

Pharma Interest

Generic Oncology Drugs Market Holds Promising Opportunities for Small Molecule Modalities

November 27, 2019

Anticipated to surpass the US$ 20 Billion mark in 2019, generic oncology drugs will witness an increased demand in the

Pharmaceutical News

Nanobiotix presented preclinical data showing NBTXR3 nanoparticles can activate the cGAS-STING pathway

April 18, 2018

NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the local treatment of cancer,

Go toTop